Oneglia AP, Szczepaniak LS, Jaffery MF, Cipher DJ, McDonald JG, Haykowsky MJ, et al
The regulatory landscape for compounded tirzepatide has shifted as the FDA addresses drug shortage designations, so availability may vary
BPC-157 reportedly induced increased levels of phosphorylation of both PAK and paxillin, while the total protein level remained unchanged
SetPoint Medical has achieved FDA approval for its novel neuroimmune modulation therapy, offering the first clinically-proven neuromodulation treatment option for rheumatoid arthritis patients
SAFETY, AEs, AND LABORATORY ABNORMALITIES The majority of AEs were classified as mild, and no patients prematurely discontinued study drug due to AEs (Table 4)